Carbonic anhydrase 9 (254-262)

Carbonic anhydrase 9 (254-262) is a synthetic peptide fragment derived from the catalytic domain of the human carbonic anhydrase IX (CAIX) enzyme, spanning amino acids 254 to 262. As a member of the carbonic anhydrase family, CAIX plays a critical role in regulating intracellular and extracellular pH, especially under hypoxic conditions commonly observed in various tumor microenvironments. The 254-262 peptide sequence represents a specific epitope within the larger protein, making it a valuable research tool for dissecting the structural, functional, and immunogenic properties of CAIX. Its biochemical relevance extends to fields such as cancer biology, enzymology, and peptide-based assay development, where it supports targeted investigations into protein interactions, antigenicity, and molecular recognition.

Epitope mapping: The 254-262 peptide serves as a defined epitope for mapping antibody binding sites on the CAIX protein. By providing a precise sequence corresponding to a region of interest, researchers can use it to evaluate the specificity and affinity of monoclonal or polyclonal antibodies raised against CAIX. This application is particularly important for the development and validation of immunodetection reagents, where accurate identification of epitope regions underpins the reliability of immunoassays and diagnostic platforms targeting CAIX expression in biological samples.

Immunological studies: The synthetic peptide is widely utilized in immunological assays such as enzyme-linked immunosorbent assays (ELISA), T cell activation assays, and peptide-MHC binding studies. By incorporating the 254-262 sequence into these platforms, investigators can assess immune recognition of the CAIX antigen, analyze T cell epitopes, and monitor antigen-specific immune responses. This is especially relevant for studies seeking to understand tumor-associated antigenicity and the mechanisms underlying immune surveillance in hypoxic tumor environments.

Peptide-protein interaction analysis: The 254-262 fragment enables detailed investigations into the interaction dynamics between CAIX and its binding partners. In vitro binding assays employing this peptide facilitate the identification and characterization of proteins, peptides, or small molecules that interact with the CAIX catalytic domain. Such studies contribute to elucidating the molecular mechanisms governing CAIX function and regulation, and provide a foundation for rational design of inhibitors or modulators targeting this enzyme.

Peptide synthesis and assay development: The defined sequence of the 254-262 peptide makes it a valuable standard for optimizing solid-phase peptide synthesis protocols and validating analytical techniques. Researchers employ it as a reference molecule to calibrate chromatographic systems, assess peptide purity, and refine mass spectrometric methods for peptide identification. This utility supports the broader field of peptide chemistry and analytical biochemistry, ensuring accurate and reproducible results in both research and quality control contexts.

Structural and functional studies: The 254-262 peptide fragment is instrumental in probing the structure-function relationship of the CAIX protein. By isolating this specific region, researchers can investigate how local sequence motifs contribute to the overall conformation, enzymatic activity, and substrate recognition of CAIX. Structural analyses using techniques such as NMR spectroscopy or X-ray crystallography, in conjunction with functional assays, help delineate the role of individual peptide segments in the broader context of protein architecture and biological activity.

1. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

2. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

3. Exosomes-mediated Transfer of miR-125a/b in Cell-to-cell Communication: A Novel Mechanism of Genetic Exchange in the Intestinal Microenvironment

4. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

5. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes